Diabetes Medication May Help Combat Triple- Negative Breast Cancer
Triple-negative breast cancers (TNBCs) account for roughly 10 to 15 percent of all breast cancers. They disproportionately affect African American and Hispanic women, young women, and women with mutations on the BRCA1 gene.
Triple-negative breast cancers (TNBCs) account for approximately 10 % to 15% of all breast cancers. They have a disproportionate impact on African American and Hispanic women , young women and women with mutations in the BRCA1 gene.
TNBCs are notoriously aggressive and difficult to treat, due in part to the limited treatment options that exist outside of chemotherapy. But according to a new study reported in the journal Nature on March 6, two drugs that have been used to treat other diseases for decades might help improve outcomes in people with TNBCs.
TNBCs are notoriously aggressive and difficult to treat, partly because of limited treatment options outside chemotherapy. However, according to a new study published in Nature on March 6, two drugs that have been used to treat other diseases for decades may help to improve outcomes in people with TNBCs.
Those two drugs are a diabetes medication called metformin and a drug for rare disorders called heme. Researchers want to know, if used together, whether they can provide effective treatment for people with TNBC. Metformin is the first-line treatment for type 2 diabetes and one of the most commonly prescribed medications in the United States.
These two drugs are a diabetes medicament called metformin and a rare disorder drug called heme. Researchers would like to know, if used together, whether they can provide effective treatment for people with TNBC. Metformin is the first-line treatment for type 2 diabetes and one of the most commonly prescribed drugs in the United States.
In recent studies, it's also been shown to have anti-cancer effects that may suppress the growth of tumors and induce the death of cancer cells in people taking the medication.However, some cancer cells are more sensitive to metformin than others.
Recent studies have also shown that anti-cancer effects can suppress tumor growth and cause the death of cancer cells in people taking the medication. However, some cancer cells are more sensitive to metformin than others.
"Because metformin, a drug used by diabetics, has been associated with decreased cancer risk, there are a number of clinical trials currently ongoing [that are) testing its role in cancer treatment," Marsha Rosner, PhD, the senior author of the study and a professor in the Ben May Department for Cancer Research at the University of Chicago, told Healthline.
"Because metformin, a drug used in diabetics, has been associated with reduced cancer risk, a number of clinical trials are currently underway [which are] testing its role in cancer treatment," said Marsha Rosner, PhD, senior author of the study and professor at the Ben May Department of Cancer Research at the University of Chicago, Healthline.
“However, currently there is no marker to predict who might benefit from metformin treatment or who might be resistant," she said.
"However, there is currently no indication as to who might benefit from metformin therapy or who might be resistant," she said.
That's where her team's research findings on another drug, heme, might prove useful.
That's where the findings of her team 's research on another drug, heme, may prove useful.
Heme is marketed under the brand name Panhematin. It's used to treat porphyrias, a group of rare disorders that can affect the skin or nervous system.
Heme is marketed under the brand name of Panhematin. It is used to treat porphyria, a group of rare disorders that may affect the skin or nervous system.
Rosner's research team used heme to inhibit the production of a protein known as BACH1, which tends to be highly expressed in TNBCs.Using a bioinformatics approach to study patient data, they found that BACH1 plays an important role in the spread of aggressive TNBCs. When they used heme to reduce levels of BACH1 in a mouse model of TNBC, they found that tumor cells in mice became more sensitive to metformin.
Rosner's research team used heme to inhibit the production of protein known as BACH1, which tends to be highly expressed in TNBCs. Using a bioinformatics approach to the study of patient data, they found that BACH1 plays an important role in the spread of aggressive TNBCs. When heme was used to reduce BACH1 levels in a mouse model of TNBC, it was found that tumor cells in mice became more sensitive to TNBC.
Mice that were treated with a combination of heme and metformin experienced reduced tumor growth. "Our work suggests one possible determinant of metformin sensitivity," Rosner said.
Mice treated with a combination of heme and metformin experienced reduced tumor growth. "Our work suggests one possible determinant of the sensitivity of metformin," Rosner said.
"Moreover, it implies that some patients might benefit from pretreatment with our second drug, Panhematin, she added.
"It also means that some patients may benefit from pretreatment with our second drug, Panhematin," she said.
This combination of medications might also suppress tumor growth in other types of cancer where BACH1 is highly expressed, including lung, kidney, uterus, and prostate cancers.
This combination of drugs may also suppress tumor growth in other types of cancers where BACH1 is highly expressed, including lung , kidney, uterus, and prostate cancer.
More research is needed to study the potential effects of heme and metformin in combination for TNBCs in human subjects.
Further research is needed to study the potential effects of heme and metformin in combination with TNBCs in human subjects.
But according to Dr. Alice Police, the regional director of breast surgery in Westchester County at Northwell Health Cancer Institute, these initial research findings are promising.
However, according to Dr. Alice Police, Regional Director of Breast Surgery in Westchester County at the Northwell Health Cancer Institute, these initial findings are promising.
"It's really amazing and potentially groundbreaking because it's two medications that people all over the world take all the time," Police told Healthline.
"It's really amazing and potentially groundbreaking because it's two drugs that people around the world take all the time," Police said to Healthline.
"So we already know that metformin and Panhematin have excellent safety profiles, " she continued, and are not as full of side effects as most chemotherapy and some of the harsher immunotherapy drugs." Several targeted therapies have been developed to treat other types of breast cancer, including HER2.positive breast cancers, estrogen-positive breast cancers, and progesterone positive breast cancers.
"We already know that metformin and Panhematin have excellent safety profiles," she said, "and are not as full of side effects as most chemotherapy and some of the tougher immunotherapy drugs." Several targeted therapies have been developed to treat other types of breast cancer, including HER2.positive breast cancer, estrogen-positive breast cancer, and progesterone-positive breast cancer.
But those targeted therapies don't work for TNBCs. Instead, most people with TNBCs rely on toxic regimens of chemotherapy. " The chemotherapy that they're getting is really strong cytotoxic chemotherapy that has significant side effects and not great safety profiles," Police said.
But these targeted therapies are not working for TNBCs. Instead, most people with TNBCs rely on toxic chemotherapy regimens. "The chemotherapy they get is really strong cytotoxic chemotherapy, which has significant side effects and not high safety profiles," Police said.
" So the idea that there's two medications with a very low toxicity profile that might have an effect on this horrible disease is just wonderful," she added.
"The idea that there are two drugs with a very low toxicity profile that could have an effect on this horrible disease is just wonderful," she said.
To promote better outcomes in people with TNBCs, Police emphasized the importance of early diagnosis and treatment.
In order to promote better outcomes for people with TNBCs, the Police emphasized the importance of early diagnosis and treatment.
" Like other breast cancers, a small early triple-negative (tumor) is way easier to treat and has a way better prognosis than a big late one," she said.
"As with other breast cancers, a small early triple-negative (tumor) is much easier to treat and has a much better prognosis than a large late one," she said.
" So patients need to get their mammograms," she said.
"The patients need to get their mammograms," she said.
The U.S. Preventive Services Task Force (USPSTF) recommends that women be tween ages 50 and 74 get a mammogram every two years to screen for breast cancer.
The U.S. Preventive Services Task Force (USPSTF) recommends that women between the ages of 50 and 74 should have a mammogram every two years for breast cancer screening.
In some cases, the organization notes, individuals in may choose to start mammography screening at a younger age.
In some cases , the organization notes that individuals may choose to start screening for mammography at a younger age.
The USPSTF also supports genetic risk assessments in younger women who have a family history of breast, ovarian, tubal, or peritoneal cancers. Some cases of these cancers are linked to mutations in the BRCA1 or BRCA2 gene, the first of which are associated with increased risk of TNBCs.
The USPSTF also supports the assessment of genetic risk in younger women with family history of breast , ovarian, tubal or peritoneal cancer. Some cases of these cancers are linked to mutations in the BRCA1 or BRCA2 genes, the first of which is associated with an increased risk of TNBCs.
Triple-negative breast cancers (TNBCs) account for approximately 10 % to 15% of all breast cancers. They have a disproportionate impact on African American and Hispanic women , young women and women with mutations in the BRCA1 gene.
TNBCs are notoriously aggressive and difficult to treat, due in part to the limited treatment options that exist outside of chemotherapy. But according to a new study reported in the journal Nature on March 6, two drugs that have been used to treat other diseases for decades might help improve outcomes in people with TNBCs.
TNBCs are notoriously aggressive and difficult to treat, partly because of limited treatment options outside chemotherapy. However, according to a new study published in Nature on March 6, two drugs that have been used to treat other diseases for decades may help to improve outcomes in people with TNBCs.
Those two drugs are a diabetes medication called metformin and a drug for rare disorders called heme. Researchers want to know, if used together, whether they can provide effective treatment for people with TNBC. Metformin is the first-line treatment for type 2 diabetes and one of the most commonly prescribed medications in the United States.
These two drugs are a diabetes medicament called metformin and a rare disorder drug called heme. Researchers would like to know, if used together, whether they can provide effective treatment for people with TNBC. Metformin is the first-line treatment for type 2 diabetes and one of the most commonly prescribed drugs in the United States.
In recent studies, it's also been shown to have anti-cancer effects that may suppress the growth of tumors and induce the death of cancer cells in people taking the medication.However, some cancer cells are more sensitive to metformin than others.
Recent studies have also shown that anti-cancer effects can suppress tumor growth and cause the death of cancer cells in people taking the medication. However, some cancer cells are more sensitive to metformin than others.
"Because metformin, a drug used by diabetics, has been associated with decreased cancer risk, there are a number of clinical trials currently ongoing [that are) testing its role in cancer treatment," Marsha Rosner, PhD, the senior author of the study and a professor in the Ben May Department for Cancer Research at the University of Chicago, told Healthline.
"Because metformin, a drug used in diabetics, has been associated with reduced cancer risk, a number of clinical trials are currently underway [which are] testing its role in cancer treatment," said Marsha Rosner, PhD, senior author of the study and professor at the Ben May Department of Cancer Research at the University of Chicago, Healthline.
“However, currently there is no marker to predict who might benefit from metformin treatment or who might be resistant," she said.
"However, there is currently no indication as to who might benefit from metformin therapy or who might be resistant," she said.
That's where her team's research findings on another drug, heme, might prove useful.
That's where the findings of her team 's research on another drug, heme, may prove useful.
Heme is marketed under the brand name Panhematin. It's used to treat porphyrias, a group of rare disorders that can affect the skin or nervous system.
Heme is marketed under the brand name of Panhematin. It is used to treat porphyria, a group of rare disorders that may affect the skin or nervous system.
Rosner's research team used heme to inhibit the production of a protein known as BACH1, which tends to be highly expressed in TNBCs.Using a bioinformatics approach to study patient data, they found that BACH1 plays an important role in the spread of aggressive TNBCs. When they used heme to reduce levels of BACH1 in a mouse model of TNBC, they found that tumor cells in mice became more sensitive to metformin.
Rosner's research team used heme to inhibit the production of protein known as BACH1, which tends to be highly expressed in TNBCs. Using a bioinformatics approach to the study of patient data, they found that BACH1 plays an important role in the spread of aggressive TNBCs. When heme was used to reduce BACH1 levels in a mouse model of TNBC, it was found that tumor cells in mice became more sensitive to TNBC.
Mice that were treated with a combination of heme and metformin experienced reduced tumor growth. "Our work suggests one possible determinant of metformin sensitivity," Rosner said.
Mice treated with a combination of heme and metformin experienced reduced tumor growth. "Our work suggests one possible determinant of the sensitivity of metformin," Rosner said.
"Moreover, it implies that some patients might benefit from pretreatment with our second drug, Panhematin, she added.
"It also means that some patients may benefit from pretreatment with our second drug, Panhematin," she said.
This combination of medications might also suppress tumor growth in other types of cancer where BACH1 is highly expressed, including lung, kidney, uterus, and prostate cancers.
This combination of drugs may also suppress tumor growth in other types of cancers where BACH1 is highly expressed, including lung , kidney, uterus, and prostate cancer.
More research is needed to study the potential effects of heme and metformin in combination for TNBCs in human subjects.
Further research is needed to study the potential effects of heme and metformin in combination with TNBCs in human subjects.
But according to Dr. Alice Police, the regional director of breast surgery in Westchester County at Northwell Health Cancer Institute, these initial research findings are promising.
However, according to Dr. Alice Police, Regional Director of Breast Surgery in Westchester County at the Northwell Health Cancer Institute, these initial findings are promising.
"It's really amazing and potentially groundbreaking because it's two medications that people all over the world take all the time," Police told Healthline.
"It's really amazing and potentially groundbreaking because it's two drugs that people around the world take all the time," Police said to Healthline.
"So we already know that metformin and Panhematin have excellent safety profiles, " she continued, and are not as full of side effects as most chemotherapy and some of the harsher immunotherapy drugs." Several targeted therapies have been developed to treat other types of breast cancer, including HER2.positive breast cancers, estrogen-positive breast cancers, and progesterone positive breast cancers.
"We already know that metformin and Panhematin have excellent safety profiles," she said, "and are not as full of side effects as most chemotherapy and some of the tougher immunotherapy drugs." Several targeted therapies have been developed to treat other types of breast cancer, including HER2.positive breast cancer, estrogen-positive breast cancer, and progesterone-positive breast cancer.
But those targeted therapies don't work for TNBCs. Instead, most people with TNBCs rely on toxic regimens of chemotherapy. " The chemotherapy that they're getting is really strong cytotoxic chemotherapy that has significant side effects and not great safety profiles," Police said.
But these targeted therapies are not working for TNBCs. Instead, most people with TNBCs rely on toxic chemotherapy regimens. "The chemotherapy they get is really strong cytotoxic chemotherapy, which has significant side effects and not high safety profiles," Police said.
" So the idea that there's two medications with a very low toxicity profile that might have an effect on this horrible disease is just wonderful," she added.
"The idea that there are two drugs with a very low toxicity profile that could have an effect on this horrible disease is just wonderful," she said.
To promote better outcomes in people with TNBCs, Police emphasized the importance of early diagnosis and treatment.
In order to promote better outcomes for people with TNBCs, the Police emphasized the importance of early diagnosis and treatment.
" Like other breast cancers, a small early triple-negative (tumor) is way easier to treat and has a way better prognosis than a big late one," she said.
"As with other breast cancers, a small early triple-negative (tumor) is much easier to treat and has a much better prognosis than a large late one," she said.
" So patients need to get their mammograms," she said.
"The patients need to get their mammograms," she said.
The U.S. Preventive Services Task Force (USPSTF) recommends that women be tween ages 50 and 74 get a mammogram every two years to screen for breast cancer.
The U.S. Preventive Services Task Force (USPSTF) recommends that women between the ages of 50 and 74 should have a mammogram every two years for breast cancer screening.
In some cases, the organization notes, individuals in may choose to start mammography screening at a younger age.
In some cases , the organization notes that individuals may choose to start screening for mammography at a younger age.
The USPSTF also supports genetic risk assessments in younger women who have a family history of breast, ovarian, tubal, or peritoneal cancers. Some cases of these cancers are linked to mutations in the BRCA1 or BRCA2 gene, the first of which are associated with increased risk of TNBCs.
The USPSTF also supports the assessment of genetic risk in younger women with family history of breast , ovarian, tubal or peritoneal cancer. Some cases of these cancers are linked to mutations in the BRCA1 or BRCA2 genes, the first of which is associated with an increased risk of TNBCs.
Comments
Post a Comment